- Ampio Pharmaceuticals (AMPE) is trading 6.6% lower premarket.
- Likely behind the move is TheStreet's Adam Feuerstein who, in a response to an article by SA contributor Brian Wilson, says the company "slipped in" new disclosures regarding Optina in the prospectus for its most recent financing.
- According to Feuerstein, the company's disclosure that "the FDA has previously indicated that a Phase 3 trial may be necessary following the current trial" is quite a change of pace from the language present in AMPE's March 10-Q.
- "The FDA has never approved a drug for DME based on a 12-week clinical trial," Feuerstein says.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs